Invitae Corporation (NYSE:NVTA), a genetic information company, is
presenting seven posters at the 2015 American College of Medical
Genetics (ACMG) Annual Clinical Genetics Meeting, including data
demonstrating the use of next-generation sequencing (NGS) technology in
genetic testing, a proposed variant classification system based on ACMG
guidelines, and genetic testing case studies.
Invitae also announced that it has expanded its test catalog to include
four new cancer-related genes, as well as full coverage of CHEK2, a gene
associated with increased cancer risk.
“The field of genetics is changing rapidly, and the discovery of the
correlation between genes and hereditary disorders is vastly improving
patient care. The ability to order full CHEK2—an important option for
patients with a personal and family history of breast cancer—is a great
example of this,” said Invitae’s Federico Monzon, MD. “Furthermore,
Invitae’s offering provides clinicians with an affordable and
customizable approach for their patients.”
The new genes include BARD1, MRE11A, RAD50 and CTRC. Invitae has
introduced one
new multi-gene panel and updated several other panels to incorporate
the new genes.
“All Invitae panels with CHEK2 will now offer full coverage of the gene,
which is known to play a role in hereditary breast cancer and possibly
other cancers, and will enable us to serve more customers and help more
patients understand their genetic risk,” said Sean George, president and
chief operating officer of Invitae. “This important addition to our test
menu is the result of a series of process improvements that we believe
will enable us to further expand our test menu throughout the course of
the year while maintaining our strategy of lowering the cost of genetic
testing. The ongoing expansion of Invitae’s test catalog marks an
important step toward the company’s goal of bringing comprehensive,
affordable genetic information into mainstream medical practice to
improve the quality of healthcare for billions of people.”
Learn more about Invitae’s new and updated panels here.
About Invitae
Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic
information into mainstream medical practice to improve the quality of
healthcare for billions of people. Currently focused on hereditary
cancers, Invitae’s goal is to aggregate most of the world’s genetic
tests into a single service with higher quality, faster turnaround time
and lower price than many single-gene tests today. The company currently
provides a single diagnostic service comprising over 200 genes for a
variety of genetic disorders associated primarily with cancer, but also
covering cardiology, hematology, neurology and pediatrics.
Safe Harbor Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the benefits and attributes of the
company’s tests; the belief that process improvements will allow the
company to further expand its test menu and maintain its strategy of
lowering the cost of genetic testing; and the belief that expansion of
its test catalog marks an important step toward the company’s goal of
bringing comprehensive genetic information into mainstream medical
practice to improve the quality of healthcare. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the company's history of
losses; the company’s need to scale its infrastructure in advance of
demand for its tests and to increase demand for its tests; the company’s
ability to develop and commercialize new tests and expand into new
markets; the risk that the company may not obtain or maintain sufficient
levels of reimbursement for its tests; risks associated with the
company’s ability to use rapidly changing genetic data to interpret test
results accurately and consistently; the company’s ability to compete;
laws and regulations applicable to the company’s business, including
potential regulation by the FDA; and the other risks set forth in the
company's filings with the Securities and Exchange Commission, including
the risks set forth in the company's Registration Statement on Form S-1
(including the final prospectus dated February 11, 2015). These
forward-looking statements speak only as of the date hereof, and Invitae
Corporation disclaims any obligation to update these forward-looking
statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the property of
their respective owners.
Copyright Business Wire 2015